CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,719,562
- in 13 filings, $45.5M under 10b5-1 plans
Net −$85,719,562. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-10-21 | Venker Eric President & COO | Sale | −100,000 | $11.65 | $1.2M | 617,470 |
| 2024-10-21 | Venker Eric President & COO | Option exercise · Stock Option (Right to Buy) | −100,000 | 12,426,234 | ||
| 2024-10-20 | Venker Eric President & COO | Shares withheld for taxes | −10,945 | $11.92 | $130K | 617,470 |
| 2024-10-20 | Kumar Rakhi Chief Accounting Officer | Shares withheld for taxes | −956 | $11.92 | $11K | 208,366 |
| 2024-10-20 | Gline Matthew CEO | Shares withheld for taxes | −10,945 | $11.92 | $130K | 17,361,059 |
| 2024-09-28 | Pulik Richard CFO | Shares withheld for taxes | −2,340 | $11.48 | $27K | 281,283 |
| 2024-09-26 | QVT Financial LP Director by Deputization | Sale | −876,000 | $11.82 | $10.4M | 22,179,358 |
| 2024-09-26 | Gold Daniel Allen Director | Sale | −876,000 | $11.82 | $10.4M | 22,179,358 |
| 2024-09-25 | QVT Financial LP Director by Deputization | Sale | −50,000 | $11.77 | $589K | 23,055,358 |
| 2024-09-25 | MANCHESTER KEITH S Director | Sale | −134,948 | $11.77 | $1.6M | 1,277,178 |
| 2024-09-25 | Gold Daniel Allen Director | Sale | −991,593 | $11.77 | $11.7M | 4,731,830 |
| 2024-09-25 | Gold Daniel Allen Director | Sale | −365,551 | $11.77 | $4.3M | 1,713,508 |
| 2024-09-25 | Gold Daniel Allen Director | Sale | −50,000 | $11.77 | $589K | 23,055,358 |
| 2024-09-24 | MANCHESTER KEITH S Director | Sale | −368,052 | $11.63 | $4.3M | 1,412,126 |
| 2024-09-24 | Gold Daniel Allen Director | Sale | −1,565,670 | $11.63 | $18.2M | 5,723,423 |
| 2024-09-24 | Gold Daniel Allen Director | Sale | −577,186 | $11.63 | $6.7M | 2,079,059 |
| 2024-09-23 | Kumar Rakhi Chief Accounting Officer | Option exercise 10b5-1 | +250,000 | $3.85 | $963K | 459,322 |
| 2024-09-23 | Kumar Rakhi Chief Accounting Officer | Sale 10b5-1 | −250,000 | $11.89 | $3.0M | 209,322 |
| 2024-09-23 | Kumar Rakhi Chief Accounting Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −250,000 | 500,000 | ||
| 2024-09-23 | Gline Matthew CEO | Option exercise 10b5-1 | +1,550,000 | $3.85 | $6.0M | 19,853,800 |
Page 28 of 29 · 570 trades